PharmaEssentia (6446)

Currency in TWD
779.00
+16.00(+2.10%)
Closed·
6446 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
751.00780.00
52 wk Range
440.00796.00
Key Statistics
Bid/Ask
91.40 / 91.50
Prev. Close
565
Open
780
Day's Range
751-780
52 wk Range
440-796
Volume
2.31M
Average Volume (3m)
2.86M
1-Year Change
16.2687%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
6446 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
733.05
Downside
-5.90%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

PharmaEssentia News & Analysis

Show more

PharmaEssentia Company Profile

PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. Its products include Ropeginterferon alfa-2b that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. The company also develops TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint abs for the treatment of solid tumors; P1101 + anti PD-1 for the treatment of hepatocellular carcinoma; and PEG-GCSF for the treatment of neutropenia. In addition, it focuses on the drug research and development programs in the areas of hematology, infectious disease, and oncology. PharmaEssentia Corporation was founded in 1990 and is headquartered in Taipei, Taiwan.

Employees
131
Market
Taiwan

Compare 6446 to Peers and Sector

Metrics to compare
6446
Peers
Sector
Relationship
P/E Ratio
58.7x0.0x−0.6x
PEG Ratio
0.370.000.00
Price/Book
9.5x0.0x2.6x
Price / LTM Sales
20.4x0.0x3.3x
Upside (Analyst Target)
−11.3%0.0%45.0%
Fair Value Upside
Unlock0.0%6.5%Unlock

Analyst Ratings

5 Buy
1 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 733.05
(-5.90% Downside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 12.95%
Dividend Yield
0.13%
Industry Median 0.64%
Annualised payout
0.99
Paid annually
5-Years Growth
-
Growth Streak

Earnings

Latest Release
Nov 04, 2025
EPS / Forecast
3.99 / 4.09
Revenue / Forecast
3.89B / 4.04B
EPS Revisions
Last 90 days

People Also Watch

936.00
2404
+2.41%
560.00
6139
+0.90%
3,855.00
7769
+2.80%
947.00
1519
+0.53%
1,830.00
6442
+7.02%

FAQ

What Is the PharmaEssentia (6446) Share Price Today?

The live PharmaEssentia share price today is 779.00

What Stock Exchange Does PharmaEssentia (6446) Trade On?

PharmaEssentia is listed and trades on the Taiwan Stock Exchange.

What Is the Ticker (Stock Symbol) for PharmaEssentia?

The stock symbol (also called a 'ticker') for PharmaEssentia is "6446."

Does PharmaEssentia Pay Dividends? What’s The Current 6446 Dividend Yield?

Yes, 6446 Pays Dividends to its Shareholders. The current PharmaEssentia dividend yield is 0.13%.

What Is the Current PharmaEssentia Market Cap?

As of today, PharmaEssentia market capitalisation is 281.82B.

What Is PharmaEssentia's (6446) Earnings Per Share (TTM)?

The PharmaEssentia EPS is currently 12.95 (Trailing Twelve Months).

When Is the Next PharmaEssentia Earnings Date?

PharmaEssentia's next earnings report will be released on 03 Mar 2026.

Is 6446 a Buy or Sell From a Technical Analyst Perspective?

Based on today's PharmaEssentia moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has PharmaEssentia Stock Split?

PharmaEssentia has split 3 times. (See the 6446 stock split history page for full effective split date and price information.)

How Many Employees Does PharmaEssentia Have?

PharmaEssentia has 131 employees.

What is the current trading status of PharmaEssentia (6446)?

As of 04 Feb 2026, PharmaEssentia (6446) is trading at a price of 779.00, with a previous close of 565.00. The stock has fluctuated within a day range of 751.00 to 780.00, while its 52-week range spans from 440.00 to 796.00.

What Is PharmaEssentia (6446) Price Target According to Analysts?

The average 12-month price target for PharmaEssentia is TWD733.05, with a high estimate of TWD1090 and a low estimate of TWD550. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an -5.90% Downside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.